Azfar Sheikh, MD
Interventional Cardiology · Houston, TXNPI 1407295736
Payments from drug & device makers
Across 231 payments — averaging $72.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$4K
- Angiodynamics, Inc.$3K
- Edwards Lifesciences$1K
- Amgen$629
- Medtronic$572
- plus $3K from 28 others
What the payments were for
- Grants$3,00018%
- Travel & lodging$2,60616%
- Food & beverage$8,02448%
- Education$1,1427%
- Other$1,92012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $4,243 |
| Boston Scientific | 44 | $3,937 |
| Angiodynamics, Inc. | 5 | $3,005 |
| Edwards Lifesciences | 13 | $1,334 |
| Amgen | 34 | $629 |
| Medtronic | 12 | $572 |
| Abiomed | 7 | $510 |
| Novartis | 16 | $301 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $282 |
| AstraZeneca | 6 | $280 |
| Merck | 12 | $198 |
| Cvrx, Inc. | 3 | $186 |
| Cardiovascular Systems Inc. | 3 | $166 |
| Johnson & Johnson | 7 | $143 |
| E.r. Squibb & Sons, L.L.C. | 7 | $121 |
| Philips North America LLC | 1 | $112 |
| Tactile Systems Technology Inc | 4 | $82 |
| Octapharma USA, Inc. | 1 | $72 |
| Actelion Pharmaceuticals US, Inc. | 3 | $72 |
| Impulse Dynamics (USA) Inc. | 3 | $58 |
| Pfizer | 3 | $53 |
| Inari Medical, Inc. | 1 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Endologix LLC | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Itamar Medical Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Atricure, Inc. | 1 | $16 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$2,963
- CROSSBOSS$2,037
- OPTIS$468
- Impella$267
- SYNERGY$228
- ANGIOJET$192
- AMPLATZER AMULET$159
- AMPLATZER Occluders$153
- WATCHMAN Access System$150
- Barostim Neo System$144
- MitraClip System$143
- Resolute$133
- Peripheral Orbital Atherectomy System$127
- Coronary Orbital Atherectomy System$127
- AVVIGO Guidance System$126
- BRILINTA$125
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$119
- HawkOne$117
- (9520) IGT Devices Undivided$112
- ILAB$111
How this compares
$16,693 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 174 | $152,778 |
| Repatha SureclickEvolocumab | 80 | $60,142 |
| EntrestoSacubitril/Valsartan | 27 | $36,689 |
| XareltoRivaroxaban | 19 | $16,641 |
| Amiodarone Hcl | 87 | $3,179 |
| Ranolazine ErRanolazine | 17 | $2,673 |
| Atorvastatin Calcium | 256 | $2,298 |
| Metoprolol Succinate | 183 | $1,849 |
| Clonidine | 15 | $1,669 |
| Carvedilol | 141 | $1,085 |
| Amlodipine Besylate | 152 | $1,064 |
| ClopidogrelClopidogrel Bisulfate | 128 | $1,037 |
| Potassium Chloride | 84 | $1,017 |
| Nifedipine ErNifedipine | 42 | $983 |
| Rosuvastatin Calcium | 55 | $904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $152,778174 claims |
| NovartisEntresto | $301 | $36,68927 claims |
| Johnson & JohnsonXarelto | $143 | $16,64119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.